Bleakley Financial Group LLC Boosts Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bleakley Financial Group LLC grew its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 63.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,739 shares of the biotechnology company’s stock after buying an additional 6,498 shares during the period. Bleakley Financial Group LLC’s holdings in ADMA Biologics were worth $287,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ADMA. Creative Planning grew its stake in shares of ADMA Biologics by 73.9% in the 2nd quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 15,363 shares during the period. CWM LLC lifted its holdings in shares of ADMA Biologics by 72.5% in the 3rd quarter. CWM LLC now owns 14,129 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 5,937 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 888 shares during the last quarter. Inspire Advisors LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $417,000. Finally, Veracity Capital LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $427,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

ADMA has been the topic of several recent analyst reports. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $15.88 on Wednesday. ADMA Biologics, Inc. has a 12-month low of $5.02 and a 12-month high of $23.64. The stock has a market cap of $3.75 billion, a P/E ratio of 56.71 and a beta of 0.75. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $17.58 and a 200-day simple moving average of $17.75.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.